Biotechnology Companies in Denmark

Aquaporin is an innovative water technology company with operations in Denmark (HQ), Singapore, Turkey, the United States, and China. We are committed to rethinking water filtration with biotechnology to solve global water challenges. By combining three disciplines from the world of natural sciences: biology, chemistry, and physics, we have created the unique, nature-inspired Aquaporin Inside® technology which we embed into all our membranes and solutions. Our technology is based on Nobel Prize-winning research and is used to clean and reuse water in industries, in our homes, and even by NASA in space. We work with customers and partners around the globe to responsibly treat industrial wastewater, concentrate food and beverage products in a natural way, and enhance drinking water quality and accessibility.

We are a Danish biotech startup based in Søborg, with global ambition. We created superior material from nature's most abundant building block, cellulose.

PentaBase is a knowledge-based Danish pharmacogenomics company founded and managed by researchers and located in the heart of Denmark. We specialise in custom oligonucleotide production and the development of in vitro diagnostic assays for real-time PCR with a special focus on the detection of somatic mutations in cancer and COVID-19. For more than 10 years, PentaBase has created products for researchers and medical professionals exploring new treatments and helping patients worldwide. Our products are given unique abilities in the analysis and manipulation of genetic material with our proprietary technology, INAs® (Intercalating Nucleic Acids). Medical professionals and researchers use these features to help treat diseases and acquire new knowledge. We believe in open-platform designs and strive to make our products compatible with basic instruments used in molecular biology facilities worldwide. For more information, please contact us at: Tel: +45 3696 9496 Mail: info@pentabase.com https://www.pentabase.com/

Unseen Bio is introducing the groundbreaking product Digital Gut within the preventive healthcare industry. Your gut consists of a unique and vast ecosystem of microorganisms; the gut microbiome. Bacteria, viruses, and fungi thrive here and they are specialized in coexisting with you. Jointly they perform a variety of tasks that remarkably influence the health and wellbeing of their host - you. In the past, little attention has been paid to the gut microbiome but this new booming scientific field suggests the role of the microbiome as a means to prevent, predict and treat conditions in the bowel and other parts of the human body. Today understanding, maintaining, and optimizing your highly individual gut microbiome is the future for good health, wellbeing, and body performance. We unleash the health tech potential of stool data by analyzing the gut microbiota using next generation gut bacteria sequencing. Unseen Bio is a Danish biotech company.

Founded in 2018, Abzu® is unlocking the future of drug discovery by transcending the limitations of black-box AI and ordinary analytics. Abzu established itself as a global leader in explainable AI and drug discovery by contributing to new discoveries in RNA therapeutics and disease understanding. Today, Abzu specializes in applying its expertise in siRNA, saRNA, ASOs, and anti-miRNA and its proprietary, explainable AI technology to build the future of RNA therapeutics.

Chr. Hansen has combined with Novozymes to become Novonesis: linkedin.com/company/novonesis. This global biosolutions company of 10,000 people is transforming how the world produces, consumes and lives. In 30-plus industries, its biosolutions help businesses meet their needs and the needs of our planet. Chr. Hansen was founded in 1874 by the Danish pharmacist Christian D. A. Hansen who invented an industrial process to extract rennet for cheese making. The company was a microbial powerhouse that developed natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. Its unique microbial and fermentation technology platforms and collection of around 50,000 microbial strains helped it meet its commitment to grow a better world. Naturally. In December 2022, Chr. Hansen and Novozymes entered into an agreement to create a leading global biosolutions partner by combining the two companies. The goal was to unleash the full potential of biosolutions and generate significant value for all stakeholders and society. The combination was completed on January 29, 2024, and Novonesis was born. The name means ‘a new beginning’ and is derived from the Greek word ‘genesis’. It reflects a new era where we’ll better our world with biology. You can find Novonesis on LinkedIn here: linkedin.com/company/novonesis. Chr. Hansen A/S, part of Novonesis Group.

Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.

Adcendo seeks to develop antibody-drug conjugates to create new medicines for cancer patients with a significant unmet need. The company was founded in 2017 in Copenhagen, as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen.

Antag Therapeutics is based on years of collaborative research from the University of Copenhagen with the focus on novel treatments for dietary-related metabolic diseases. The research teams of professors Mette M. Rosenkilde and Jens J. Holst have discovered naturally occurring therapeutic peptides that are being investigated in several human studies.

AFYX Therapeutics is a private biopharmaceutical company focused on innovative approaches to treat mucosal diseases. The Company has developed the Rivelin patch, a breakthrough therapy for the treatment of mucosal diseases. Rivelin is designed to deliver a pharmaceutical drug uni-directionally to a mucosal surface using an occlusive, bio-adhesive and bio-degradable patch, with a long adhesion time and a high flexibility, conforming to the mucosal surface. AFYX's lead Rivelin patch product candidate seeks to treat the auto-immune, inflammatory disease oral lichen planus (OLP) through direct delivery of the drug clobetasol propionate. OLP may appear as lesions in the mouth that may cause burning, pain and other discomfort. OLP is considered an autoimmune disorder and requires regular monitoring given patients have increased risk of developing mouth cancer in the affected areas. No U.S. Food and Drug Administration (FDA) approved treatment exists, with today’s off-label treatment ranging from topical corticosteroids to laser ablation. It is estimated that OLP affects 1% to 2% of the population. Following successful results from a Phase 1b clinical study of the non-drug-loaded Rivelin patch in patients with OLP, AFYX has begun a Phase 2b clinical study of the clobetasol-loaded Rivelin patch in the United States and various countries in Europe. Shareholders include Sofinnova Ventures, Lundbeckfonden Emerge, Novo Seeds and Welfare Tech Invest.

Mission NMD Pharma is dedicated to developing novel treatments to improve muscle function and quality of life of patients with neuromuscular disease. Vision A future in which patients with neuromuscular disease live better and more independent lives. We have a unique translational muscle electrophysiology platform leveraging in-depth know-how of muscle physiology and muscular disorders for discovering and developing first-in-class therapeutics in neuromuscular diseases with a significant unmet medical need. NMD Pharma is the leading company utilizing ClC-1 Cl- ion channel inhibitors for neuromuscular diseases and currently has one clinical-stage product candidate for the treatment of myasthenia gravis. We have more than 25 employees with expertise in all areas of drug development. We are headquartered in Aarhus, Denmark, and collaborate with internationally renowned companies and key opinion leaders in the field of neuromuscular diseases. For more information, please visit the company website.

We are the CRISPR and Gene Therapy of the Microbiome company! Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota. Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.

UniqAir er en finsk cleantech virksomhed, der fremstiller og leverer specialudviklede systemer til den offentlige og private sektor. UniqAir’s system har verdens mest effektive sundhedsfiltre og er testet af Teknologisk Institut i Aarhus, VTT (Finlands Teknologiske Institut) og TTL (Finlands Arbejdssundhedsinstitut). UniqAir’s filtre fjerner 99.9% af synlige og usynlige partikler samt 100% af forurenende luftarter. UniqAir leverer effektiv og hurtig hjælp ved indeklimaproblemer i kommuner, regioner, social- og sundhedspleje, uddannelsesinstitutioner og virksomheder. Læs mere på www.uniqair.dk

VI ER SPECIALISTER - SÅ DU IKKE BEHØVER AT VÆRE DET Foruden at være den mest profitable markedsføringskanal, så er e-mail marketing også en kanal med en bred vifte af muligheder indenfor både B2B og B2C. Fælles for de to er, at man med e-mail marketing kan skabe en tættere kunderelation, øge livstidsværdien for kunden samt få et bedre indblik i og påvirkning på kunderejsen. Med en gennemtænkt e-mail marketing strategi kan du sikre, at du automatiseret kan påvirke dine kunder med tilpassede budskaber hele vejen gennem kunderejsen samtidig med, at du øger livs- tidsværdien, forbedrer kunderelationen og øger din omsætning. Mulighederne er endeløse, når det kommer til e-mail marketing! DER ER MANGE GRUNDE TIL AT SAMARBEJDE MED OS 👇🏼 Vi er et e-mail marketing bureau med øje for udvikling af danske virksomheder. Vi vil levere en service og kvalitet, der sætter standarden inden for vores branche, og være den specialiserede samarbejdspartner, som skaber en profitabel forskel. Skal vi hjælpe dig?

I Levinsen A/S arbejder vi for at levere de bedste skov-, løv- og buskfrø til kunderne hvert år. Busk-, løv- og skovfrø er naturprodukter, og derfor påvirkes det årlige høstresultat af udsving i vækstforhold, vejr og vind. Derfor arbejder vi også med en lagerstrategi på vore største produktgrupper indenfor såvel nåletræ, som løvtræ og buskfrø. I løbet af de sidste par år har vi sikret leverance af Nordmannsgranfrø fra Georgien, ved at skaffe 10- og 20-årige høstlicenser til udvalgte lokaliteter i Ambrolauri og Borjomi Skovdistrikter. Vi henter også frø i udvalgte lokaliteter i Apsheronsk Skovdistrikt, hvilket er sikret gennem aftaler med de regionale myndigheder. Levinsen har gennem mange år, også i tidligere firmakonstellationer, arbejdet med dokumentation af provenienssikkerheden for det frø vi importerer til Danmark og sender videre til kunder herhjemme og i udlandet. Det kvalitetssikringssystem, som vi igennem en årrække har oparbejdet og udviklet, er vi i gang med at ISO-certificere sammen med de procedurer omkring arbejdsvilkår og socialt ansvar, som vi anvender for vores udenlandske arbejdskraft. Vi samarbejder med en række private skovejere i Danmark og udlandet om høst, forarbejdning og levering af kvalitetsfrø fra kårede bevoksninger og udpegede frøkilder. Vi arbejder kontinuerligt på at tilbyde de bedste frøkilder, herunder indsamle erfaringer fra praktikere og opsøge nyt materiale, hvor behovet viser sig. Vi har opbygget egne frøkilder af Nordmannsgran i Danmark, og i de senere år har vi etableret indsamling af diverse løv- og buskfrøarter rundt omkring i Danmark i samarbejde med private lodsejere. I dialog med fagfolk - bl.a. Frøkildeudvalget og KU-LIFE - har vi lagt vægt på genetisk brede frøkilder, som hører hjemme i den danske flora, og samtidig møder vore kunders behov.

Mikrolab Aarhus A/S tænker ud af boksen, når det kommer til løsning af problematikker og behov i dit laboratorium. Vi finder det produkt eller bygger den løsning, der passer til dit laboratorieworkflow og gør din arbejdsdag bedre - et workflow med høj kvalitet og fleksibilitet. Vi er et uafhængigt firma med udvikling, produktion, lager og salg i Danmark – vi udnytter vores uafhængighed og innovative produktion til skabe de bedste rammer for dig som kunde - Doing more with less.

At VikingGenetics, we breed healthy, efficient, trouble-free cows. We provide science-based bovine genetic products and solutions for progressive dairy and beef producers around the world. Our passion is to help you as a farmer achieve your business goals, farm sustainably, and enjoy life. As a co-operative, VikingGenetics has 16,000 members - dairy and beef farmers from Denmark, Sweden, and Finland. We focus on animal welfare, food security, and reducing climate impact in our entire production chain. We partner with universities, research organisations, and experts across the globe to give you tools and technology to select the best bulls. With our solutions, you can continuously improve the genetic gain for each generation of your herd. Our results are rooted in the long-term relationships with our farmers and the close link between research and implementation. Our commitment is to lead the dairy and beef industry in finding solutions to lower methane emissions and breed long-lasting climate-friendly cows.

SecondCircle makes carbon negative chemicals for a cleaner future. We are the first carbon negative chemical manufacturer that can scale to meet global demand. The best thing about it: we use carbon dioxide as a feedstock. We have raised over $50m to date from top venture capital investors as well as in grant funding from the European Union’s Horizon 2020 programme. Join us in the fight against climate change.

The active and stabilizing ingredients in detergents, soaps and cosmetics are now made from either, palm oil, fossil oil or a combination hereof. These sources are not sustainable as they contribute to the destruction of biodiverse habitats and emit large amounts of greenhouse gases. NorFalk rethinks the production of these ingredients from sustainable sources. Our process technology is innovative with novel sourcing of raw materials. With our technology, a minimal amount of waste is generated in the production by recycling chemicals and materials which reduce greenhouse gas emissions.

At Again we put CO₂ to good use. By combining millennia-old bacteria with cutting-edge technology, we turn CO₂ into carbon negative chemicals. Our novel biomanufacturing process collects the unavoidable carbon outputs from industry and reuses them to manufacture emission-free chemicals - a win-win for everyone. We’re leading the positive shift. Showing people that our world does have a future. If you think we’re doomed – think Again.

VetCur is the leading authority and innovative biotechnological partner, developing tailored species specific diets for animals, worldwide. Through our inspiration by nature and the power of science, we are obligated to set up new feeding standards for the planet as a whole and animals in particular. The millions of years in which nature and all living organisms have evolved, an enormous potential for technological innovation has been provided by nature itself. Roughly only about 12% of the potential knowledge available is used to develop new products, and create innovative solutions. VetCur is successfully tapping into the wast yet unharvested technological potential, creating innovative health solutions for animals, by integrating productivity, sustainability, biological adequacy, animal wellfare and environmental care. In summary our three values are: * Innovation * Responsibility * Sustainable growth.

We are developing the future of drug discovery with a platform to discover, develop, and deliver drug candidates for challenging targets.